Answers are grounded in this paper and cite their sources.
Venous thromboembolism is common in cancer patients, and guidelines to prevent and treat cancer-associated VTE are changing with new evidence. DOACs are increasingly becoming popular due to their efficacy, reasonable safety, and convenience to use, replacing the previous standard of care LMWH. Although more clinicians are using DOAC in the treatment and prevention of VTE many international society guidelines are still reluctant to accept DOAC as a first-line agent. This review article will summarize old and recent studies to compare the safety and efficacy of different anticoagulation options.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: